LEXINGTON, Mass. — Agenus Inc., a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer (CRC), both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High...
Latest News
LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. Munich, Germany — Colorectal cancer (bowel cancer) is the third most common form of cancer worldwide, with around 1.9 million newly diagnosed cases and 900,000 deaths every year. Therefore, preventive substances represent an urgent clinical need....
GRAND RAPIDS, Mich. – Six-year-old Jacob Geer takes 12 pills every day to control his seizures, is fed by a tube and regularly visits a variety of doctors. He will be lucky to celebrate his 12th birthday. One year ago, Jacob was diagnosed with Batten disease, a genetic disorder of...
BOSTON, Mass. — BPGbio, Inc. a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today will announce new data from a phase 2a clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held January...
Brain Boost: Can a Coach Help Elders at Risk for Alzheimer’s? San Francisco, CA – Study shows cognitive improvements when participants keep active and socially engaged, control blood pressure and diabetes. As more medications move towards federal approval for Alzheimer’s disease, a new study led by researchers at UC San...
Jackson, Wyoming – Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy Temozolomide (TMZ). Even for those patients, the cancer cells quickly evolve resistance. Most patients pass away within 12 to...
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the...
Heidelberg, Germany – Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor. By analyzing individual cells, a team of researchers from the Hopp Children’s Cancer Center Heidelberg...
FDA recommended generating additional clinical data to meet FDA’s BLA requirements NEW YORK – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received...
NEW YORK and SOMERSET, N.J. – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that...